Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(17/week)
India
(8/week)
Singapore
(2/week)
China, P. R.
(1/week)
Philippines
(1/week)
View all
(31/week)
News
United States
(1121/week)
Manufacturing
(562/week)
Technology
(1133/week)
Energy
(412/week)
Other Manufacturing
(384/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Moleculin Biotech, Inc.
Aug 19, 2024
Moleculin Announces Closing of up to $16.5 Million Public Offering
Aug 16, 2024
Moleculin Announces Pricing of up to $16.5 Million Public Offering
Aug 14, 2024
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 05, 2024
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET
Aug 01, 2024
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
Jul 10, 2024
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
Jun 14, 2024
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial
Jun 12, 2024
Moleculin to Present at the Virtual Investor Pitch Conference
Jun 05, 2024
Moleculin to Participate in the Virtual Investor Lunch Break Series
May 16, 2024
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
May 15, 2024
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
May 13, 2024
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
May 07, 2024
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
May 02, 2024
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
May 01, 2024
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Apr 18, 2024
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Apr 10, 2024
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Mar 28, 2024
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Mar 27, 2024
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Page 1
››
Latest News
Sep 1, 2024
Insta Max 20K Puffs Vape: The Future of Vaping Has Arrived
Sep 1, 2024
Kodiak Gas Services Announces 2023 Schedule K-3 Investor Tax Packages for CSI Compressco LP Are Available...
Aug 31, 2024
Suzano completes purchase of 15% stake in Lenzing AG
Aug 31, 2024
Noble Corporation plc announces changes to its share capital including share repurchases for the month of...
Aug 31, 2024
FP Markets Wins Double at FMPS 2024
Aug 31, 2024
Kenya airport workers' union delays strike again
Aug 31, 2024
CGTN: China, Africa set to embrace closer economic, trade ties at FOCAC
Aug 31, 2024
United Imaging Healthcare Reports nearly 30% YoY Growth in Overseas Market Revenue, H1 Revenue Reaches 5.33...
View all News
Agenda
29
October
United Kingdom
Copthorne Tara Hotel, London, UK
International Dismounted Soldier, 29-30 October 2024, Copthorne Tara Hotel, London, UK
Navigating the Evolving Battlespace: Enhancing the Capabilities of the Dismounted Soldier The modern battlefield...
24
September
United Kingdom
Hilton London Syon Park, London, UK
Defence Transformation Conference, 24-26 September 2024, Hilton London Syon Park, London, UK
Returning for its 8th year, Defence Transformation 2024 will feature an updated format that will address all aspects of...
View All Events